| Not Yet Recruiting | ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome NCT07531745 | Ionis Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Not Yet Recruiting | A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome NCT07013331 | Hospices Civils de Lyon | N/A |
| Not Yet Recruiting | The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project NCT07112365 | The University of Texas Health Science Center, Houston | Phase 4 |
| Recruiting | Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents NCT05126914 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene M NCT07251673 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet NCT06872125 | Stoke Therapeutics, Inc | Phase 3 |
| Completed | Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) NCT07176832 | Biocodex | Phase 1 |
| Recruiting | Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY NCT05485831 | Jazz Pharmaceuticals | — |
| Recruiting | BMB-101 in Absence Epilepsy and DEE NCT06401538 | Bright Minds Biosciences Pty Ltd | Phase 2 |
| Recruiting | A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) NCT06660394 | Longboard Pharmaceuticals | Phase 3 |
| Active Not Recruiting | A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Ye NCT06118255 | UCB BIOSCIENCES, Inc. | Phase 3 |
| Recruiting | A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dra NCT05419492 | Encoded Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children Wit NCT06283212 | Encoded Therapeutics | Phase 1 / Phase 2 |
| Active Not Recruiting | A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children Wit NCT06112275 | Encoded Therapeutics | Phase 1 / Phase 2 |
| Recruiting | SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom NCT06504511 | NHS Greater Glasgow and Clyde | — |
| Withdrawn | LEONIDaS Caregivers Study NCT05140122 | University of Oxford | — |
| Enrolling By Invitation | EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity NCT06371794 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Unknown | Fenfluramine for Adult Dravet Patients NCT05560282 | University Health Network, Toronto | Phase 3 |
| Completed | Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy NCT05626634 | Longboard Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome NCT05472389 | Hospices Civils de Lyon | N/A |
| Recruiting | GABA Biomarkers in Dravet Syndrome NCT05651204 | Cook Children's Health Care System | — |
| Completed | Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA NCT05544058 | Biocodex | — |
| Completed | Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies NCT05364021 | Longboard Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Init NCT05635266 | Sanguine Biosciences | — |
| Active Not Recruiting | Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Sol NCT05044819 | Jazz Pharmaceuticals | Phase 4 |
| Active Not Recruiting | An Open-Label Extension Study of STK-001 for Patients With Dravet Syndrome NCT04740476 | Stoke Therapeutics, Inc | Phase 2 |
| Terminated | Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies NCT04537832 | Encoded Therapeutics | — |
| Unknown | Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome NCT04614506 | Boston Children's Hospital | — |
| Recruiting | A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome NCT04462770 | Epygenix | Phase 3 |
| Completed | An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescen NCT04442295 | Stoke Therapeutics, Inc | Phase 1 / Phase 2 |
| Unknown | Research on Cognitive Effect of Cannabidiol on Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syndrome NCT04611438 | Yonsei University | Phase 3 |
| Completed | Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects. NCT04069689 | Epygenix | Phase 1 |
| Completed | A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children an NCT03936777 | Zogenix, Inc. | Phase 3 |
| Enrolling By Invitation | Early Check: Expanded Screening in Newborns NCT03655223 | RTI International | — |
| Completed | A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, a NCT03650452 | Takeda | Phase 2 |
| Withdrawn | Turmeric as Treatment in Epilepsy NCT03254680 | NYU Langone Health | N/A |
| Completed | A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Le NCT03467113 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 1 |
| Withdrawn | Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled NCT02318563 | INSYS Therapeutics Inc | Phase 3 |
| Terminated | A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Drave NCT03299842 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 3 |
| Terminated | The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy NCT02815540 | Gillette Children's Specialty Healthcare | Phase 1 / Phase 2 |
| Completed | A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safet NCT02926898 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 3 |
| Completed | Treatment of Gait Disorders in Children With Dravet Syndrome NCT03857451 | Universiteit Antwerpen | — |
| Withdrawn | The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy NCT02910297 | Gillette Children's Specialty Healthcare | — |
| Completed | An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral So NCT02823145 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 3 |
| Completed | A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome NCT02682927 | Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | Phase 3 |
| Completed | Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome NCT02896608 | Fondation Ophtalmologique Adolphe de Rothschild | — |
| Completed | An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut NCT02224573 | GW Research Ltd | Phase 3 |
| Completed | GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adul NCT02224703 | Jazz Pharmaceuticals | Phase 3 |
| Completed | Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1) NCT02091375 | Jazz Pharmaceuticals | Phase 3 |
| Withdrawn | Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome NCT02174094 | H. Lundbeck A/S | Phase 3 |
| Terminated | Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dra NCT02187809 | H. Lundbeck A/S | Phase 3 |
| Completed | A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1) NCT02091206 | Jazz Pharmaceuticals | Phase 2 |
| Completed | Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population NCT02229032 | University of Colorado, Denver | — |
| Completed | Verapamil as Therapy for Children and Young Adults With Dravet Syndrome NCT01607073 | Gillette Children's Specialty Healthcare | Phase 2 |
| No Longer Available | Stiripentol in Dravet Syndrome NCT01533506 | Mayo Clinic | — |
| Available | Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol) NCT04437004 | University of California, Los Angeles | — |
| Approved For Marketing | ZX008 Expanded Access Protocol NCT03780127 | Zogenix, Inc. | — |
| Available | Intermediate-Size Expanded Access Protocol (EAP) for LP352 NCT06149663 | Longboard Pharmaceuticals | — |
| No Longer Available | Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies NCT02239276 | Cook Children's Health Care System | — |
| Approved For Marketing | Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome NCT01983722 | Children's Hospital Medical Center, Cincinnati | — |
| No Longer Available | Compassionate Use of Stiripentol in Dravet Syndrome NCT01835314 | University of Colorado, Denver | — |